Results 41 to 50 of about 29,283 (270)

Status of liquid profiling in precision oncology – the need for integrative diagnostics for successful implementation into standard care

Journal of Laboratory Medicine, 2022
The liquid profiling approach is currently at the threshold of translation from research application in various clinical trials to introduction into the management of cancer patients in the context of clinical care.
Froelich Matthias F., Schoenberg Stefan O., Neumaier Michael, Haselmann Verena   +3 more
doaj   +1 more source

Quantification of ctDNA.

, 2023
Raw and final data with calculations of ctDNA levels before, during, and after NRT with regard to changes in tumor masses. (XLSX)
Philipp Rovedo (17319607), Matthias Jung (2866535), Konrad Kurowski (17319604), Zacharias Brugger (17319598), Hannah Fuellgraf (3584372), Anca-Ligia Grosu (126295), Balazs Bogner (17319589), Thomas Pauli (3332370), Anja Eisenhardt (17319601), Fabian Bamberg (394751), Steffen Ulrich Eisenhardt (11253360), Ute Lausch (17319592), Jurij Kiefer (766637), Alexander Runkel (17319586), Melanie Boerries (381256), Jutta Scholber (3765967), Peter Bronsert (3410321), David Braig (3765958), Anika Boneberg (17319595), Adrian Schmid (239952)   +19 more
core   +1 more source

Current and Future Clinical Applications of ctDNA in Immuno-Oncology

, 2021
Testing peripheral blood for circulating tumor DNA (ctDNA) offers a minimally invasive opportunity to diagnose, characterize, and monitor the disease in individual cancer patients.
Pantel, Klaus, Heidrich, Isabel, Keller, Laura, Gebhardt, Christoffer, Sementsov, Mark, Belloum, Yassine, Stadler, Julia-Christina, Deitert, Benjamin   +7 more
core   +1 more source

Applications of genetic-epigenetic tissue mapping for plasma DNA in prenatal testing, transplantation and oncology

eLife, 2021
We developed genetic-epigenetic tissue mapping (GETMap) to determine the tissue composition of plasma DNA carrying genetic variants not present in the constitutional genome through comparing their methylation profiles with relevant tissues.
Wanxia Gai, Ze Zhou, Sean Agbor-Enoh, Xiaodan Fan, Sheng Lian, Peiyong Jiang, Suk Hang Cheng, John Wong, Stephen L Chan, Moon Kyoo Jang, Yanqin Yang, Raymond HS Liang, Wai Kong Chan, Edmond SK Ma, Tak Y Leung, Rossa WK Chiu, Hannah Valantine, KC Allen Chan, YM Dennis Lo   +18 more
doaj   +1 more source

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer

Cancer Biology & Medicine, 2021
Objective: Anlotinib is a novel tyrosine kinase inhibitor blocking angiogenesis. This study was performed to assess the efficacy and safety of anlotinib in patients with metastatic breast cancer.
Nanlin Hu, Yiran Si, Jian Yue, Tingting Sun, Xue Wang, Zhuqing Jia, Songlin Gao, Qiao Li, Yang Shao, Jiayu Wang, Yang Luo, Fei Ma, Binghe Xu, Peng Yuan   +13 more
doaj   +1 more source

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples

Cancers, 2022
Liquid biopsy has improved significantly over the last decade and is attracting attention as a tool that can complement tissue biopsy to evaluate the genetic landscape of solid tumors. In the present study, we evaluated the usefulness of liquid biopsy in daily oncology practice in different clinical contexts.
Josep Gumà, Karla Peña, Francesc Riu, Carmen Guilarte, Anna Hernandez, Clara Lucía, Francisca Martínez-Madueño, Maria José Miranda, Inés Cabezas, Marc Grifoll, Sergio Peralta, Sara Serrano, Félix Muñoz, Lola Delamo, Barbara Roig, Joan Borràs, Joan Badia, Marta Rodriguez-Balada, David Parada   +18 more
openaire   +2 more sources

Photoactivated Platinum Complexes: Targeting Membrane Proteins and Organelles for Precision Cancer Therapy

Angewandte Chemie, EarlyView.
This review highlights an emerging anticancer approach integrating platinum agents into photodynamic therapy (PDT) and photoactivated chemotherapy (PACT) systems, further augmented by cancer cell membrane‐ and organelle‐targeting. By directing photoactivated platinum complexes from nontargeted distribution to cancer cells or defined subcellular sites ...
Shu Chen, Qiyuan Zhou, Jiaqian Xu, Guangyu Zhu   +3 more
wiley   +2 more sources

Quantitative ctDNA Detection in Hepatoblastoma: Implications for Precision Medicine

, 2023
Hepatoblastoma is characterized by driver mutations in CTNNB1, making it an attractive biomarker for a liquid biopsy approach utilizing circulating tumor DNA (ctDNA).
James Torpy, Sarah E. Woodfield, Andre E. Minoche, Anna Mullins, Sanjeev A. Vasudevan, Lucy E. Cain, Geoffrey McCowage, Smadar Kahana-Edwin, Jonathan Karpelowsky, Dan P. T. Shea, Sarah Kummerfeld, Andres F. Espinoza, Leonard D. Goldstein   +12 more
core   +1 more source

Plasma ctDNA TP53 Mutation and Breast Cancer Prognosis: A Systematic Review and Meta-Analysis

Xiehe Yixue Zazhi
ObjectiveTo analyze the association between plasma circulating tumor DNA (ctDNA) TP53 mutation status and survival outcomes in breast cancer patients.MethodsPubMed, Embase, and the Cochrane Library were searched for relevant literature published between ...
FAN Hao, LIANG Annan, ZOU Wei, GAO Guangxi, LIU Lijin, LIU Fei, ZHAO Lina, WU Zhihong   +7 more
doaj   +1 more source

Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial

, 2023
Background There is increasing interest in the use of liquid biopsies, but data on longitudinal analyses of circulating tumor DNA (ctDNA) remain relatively limited.
Joanne Chiu, Mukta Joshi, O. Alejandro Balbin, Tomoyuki Aruga, Yoon-Sim Yap, Naveen Babbar, Fei Su, Takashi Ishikawa, Juan Pablo Zarate, Norikazu Masuda   +9 more
core   +1 more source